The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Dupixent peak sales ambition raised to more than €13 billion
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Subscribe To Our Newsletter & Stay Updated
